I don’t like to look back at breaking news in our “90 Seconds” videos, but the Senate Finance Committee’s report on insulin prices is likely to have an impact that extends beyond the current news cycle, and I explain why in this week’s installment. — Brian
Welcome to Recommended Value, the W2O hub for value, access, pricing and reimbursement intelligence.
It’s never been more critical to understand the value environment, and there is no better way to stay connected with what matters than our newsletters. Our weekly Value Report (subscribe here) offers a comprehensive review, each Friday, of the week that was.
Our Recommended Daily Value newsletter — available with a paid subscriptions (get your free trial here) — brings readers the day’s news, along with original analyses and commentary, providing the information needed to make decisions in real time.
The ICER Unsupported Price Increase report dropped this week. But the most interesting — and important — part of the document had to do not with what the system spent, but rather how and why falling prices saved the health care system $2.5 billion.
Each year on New Year’s Eve, we take a crack at predicting what the next 12 months will bring. Our best bets for 2021? Action on Part D, profits from China and more.
It’s a January 1 tradition: the media swarm to cover beginning-of-the-year price increases. But those stories often leave readers more confused about the drug-pricing system. Instead, we’re hoping that reporters consider these five critical pieces of context when they pen their stories.
State transparency reports have been the rage, but are they having an impact? We looked at social sharing of 23 different reports, finding that nearly all of them generated zero — zitch, nada — social response.
The health care team for President-Elect Joe Biden is coming into focus. We’ve collected the greatest hits from his top advisors as a pre-January 20 reading list.
Each day, we summarize and analyze the day’s news in Recommended Daily Value.
The Weekly Value Report
The Impact of COVID-19 on Minority Communities in America is a Functioning Tragedy
Our Lauren Oubre spoke with Dr. Robert Fullilove, Associate Dean for Community and Minority Affairs, Professor of Clinical Sociomedical Sciences at Columbia University about racial disparities in the United States and abroad, comparing COVID-19 with HIV and explaining how pharmaceutical companies have a role in bridging gaps in care.
March-In Rights: A Brief History
“March-in rights” — a legal route by which the government can take control of intellectual property — has been in the spotlight during the Biden transition. We took a deep dive into the attempts to use the tool in the past.
Highlights from Our Redeeming Value Podcast
Nov. 4, 2020: W2O’s Courtney Tyne with Instant Analysis on the Election Results (So Far)
Nov. 2, 2020: AAM’s Dan Leonard on What’s Next for Generic Drugs and Biosimilars
Oct. 30, 2020: Ted Slafsky on 340B, How We Got Here, and Where We’re Going
Oct. 20, 2020: Peter Kolchinsky on Where Drug-Pricing Policy Solutions Go Wrong
Sept. 29, 2020: Jason Shafrin on Where — and Why — ICER Really Matters
Sept. 16, 2020: Jason Buxbaum, Medicines and Life Expectancy
RDV Image of the Week
Earlier this fall, we compiled a timeline of 340B news to help you stay up-to-date with the ongoing drama. Today, we dive into how these events have played out on social media this year. The voices are louder, the spotlight is much more on specific pharma companies than the industry as a whole, and policymakers are increasingly vocal as well.